Two biotechs recieve FDA approval, and instead of a pop, they both get stuck with double-digit drops. What should investors make of this unusual price action, and what do these companies have in front of them? Watch and find out.
Having small biotechs advance innovative new therapies isn't the only revolution disrupting the status quo. The Motley Fool has just released a free report on mobile named "The Next Trillion-Dollar Revolution" that details a hidden component play inside mobile phones that also is a market leader in the exploding Chinese market. Inside the report, we not only describe why the mobile revolution will dwarf any other technology revolution seen before it, but we also name the company at the forefront of the trend. Hundreds of thousands have requested access to previous reports, and you can access this new report today by clicking here -- it's free.
The article 2 Biotech Surprise Sell-Offs originally appeared on Fool.com.
David Williamson owns shares of Amarin, but he holds no other position in any company mentioned. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend Covidien and GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.